Evidence map›Paper›PMID 21969131›Full record

ArticleWorld journal of urology2012

CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.

Walter Henriques da Costa, Rafael Malagoli Rocha, Isabela Werneck da Cunha, Francisco Paula da Fonseca, Gustavo Cardoso Guimaraes, Stenio de Cassio Zequi

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. The role of CD133 in cancer: a concise review.Clinical and translational medicine · 2018
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Biology of renal tumour cancer stem cells applied in medicine.Contemporary oncology (Poznan, Poland) · 2015
    Review
  18. Article
  19. The relationship of cancer stem cells in urological cancers.Central European journal of urology · 2013
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Walter Henriques da CostaUrology, A.C. Camargo Hospital, Rua Cerro Cora 1540, Alto de Pinheiros, Sao Paulo, SP, Brazil. waltercosta@hotmail.com
Rafael Malagoli Rocha
Isabela Werneck da Cunha
Francisco Paula da Fonseca
Gustavo Cardoso Guimaraes
Stenio de Cassio Zequi
AC Camargo Hospital · BRHospital São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the prognostic impact of the histological expression of CD133 in renal cell carcinoma (RCC).

methodsFrom 1992 to 2009, 142 consecutive patients underwent radical nephrectomy or partial nephrectomy for RCC. All cases were reviewed by a single pathologist and then subjected to analysis of the immunohistochemical expression of CD133 using tissue microarray. Several clinical and pathological variables were also evaluated.

resultsThe median postoperative follow-up was 44 months. Of the 142 immunostained RCC specimens, 77 (54%) showed low and 65 (46%) high expression of CD133. Expression of CD133 was associated with clinical stage (P = 0.05), lymph node involvement (P = 0.03), metastatic disease (P = 0.02) and MVI (P = 0.03). Among other variables, clinical stage, necrosis and metastasis were associated with disease-specific survival (DSS) and progression-free survival (PFS) on univariate analysis. The 5-year PFS rates in patients who provided specimens with high and low expression of CD133 were 83 and 66%, respectively (P = 0.01). It was observed that the 5-year DSS for patients who provided specimens with high and low expression of CD133 was 90 and 71%, respectively (P = 0.003). Multivariate survival analysis showed that patients in the CD133 low-expression group had a higher probability of disease progression (HR 3.4, P = 0.02) and a higher probability of death from cancer (HR 2.4, P = 0.01).

conclusionsImmunohistochemical expression of CD133 had an impact on survival in patients with RCC, which shows that CD133 might be a useful tool for risk stratification. Low expression of this marker remained as an independent predictor of poor DSS and PFS.

Indexed as

Disease ProgressionAC133 AntigenAdultAgedAged, 80 and overAntigens, CDBiomarkers, TumorBiopsyCarcinoma, Renal CellFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlycoproteinsHumansImmunohistochemistryKidneyAC133 AntigenAntigens, CDBiomarkers, TumorGlycoproteinsPeptidesPROM1 protein, human

Identifiers

PMID21969131
OpenAlexW2025185222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.